Abstract
The objective of this work was to evaluate the possible role of PI3-kinase/AKT as a survival pathway against CYP2E1-dependent toxicity. E47 cells (HepG2 cells transfected with human CYP2E1 cDNA) exposed to 25 μM iron-nitrilotriacetate + 5 μM arachidonic acid (AA+Fe) developed higher toxicity than C34 cells (HepG2 cells transfected with empty plasmid). Toxicity was associated with increased oxidative stress and activation of calcium-dependent hydrolases calpain and phospholipase A2. Treatment of E47, but not C34 cells, with arachidonic acid and iron (AA+Fe) led to a decrease in the phosphorylation state of AKT. 2-(4-Morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride (LY294002), a specific inhibitor of PI3-kinase, produced a further decrease of phosphorylated AKT in AA+Fe-treated E47 cells. LY294002 and down-regulation of endogenous AKT with small interference RNAs increased the toxicity of AA+Fe in E47 cells. Toxicity of AA+Fe in rat hepatocytes was also increased by LY294002. LY294002 did not affect phospholipase A2 or calpain activation, CYP2E1 activity, or lipid peroxidation elicited by AA+Fe. α-Tocopherol prevented both AA+Fe and AA+Fe+LY294002-induced toxicity and decrease of phosphorylated AKT. LY294002 potentiated AA+Fe-induced loss of mitochondrial membrane potential and ATP, whereas overexpression of constitutively active AKT partially prevented mitochondrial impairment and toxicity. Mitochondrial permeability transition inhibitors prevented both AA+Fe and AA+Fe+LY294002-induced toxicity and decrease of mitochondrial membrane potential. These results suggest that: i) AA+Fe+CYP2E1-induced oxidative stress decreases AKT activation; ii) AKT inactivation induces mitochondrial impairment associated with opening of the permeability transition pore but is not dependent on the activation state of bad, glycogen synthase kinase-3β, mammalian target of rapamycin, or bcl-xL; and iii) PI3-kinase/AKT may serve as a survival pathway against CYP2E1-dependent toxicity.
Footnotes
-
This study was supported by United States Public Health Service Grant AA 06610 from the National Institute on Alcohol Abuse and Alcoholism.
-
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
-
doi:10.1124/jpet.106.102921.
-
ABBREVIATIONS: PI3-kinase, phosphatidylinositol 3-kinase; FK506, tacrolimus; ROS, reactive oxygen species; MTT, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; siRNA, small interference RNA; TBARS, thiobarbituric acid reactive substances; DCFH-DA, 2′,7′-dichlorofluorescein diacetate; Fe-NTA, iron-nitrilotriacetate 1:3 complex; E47 cells, HepG2 cell line derived after transfection with pCI-neo vector containing the human CYP2E1 cDNA; C34 cells, HepG2 cell line derived after transfection with pCI-neo vector; MEM, minimal essential medium; MEMexps, MEM medium supplemented with 5% fetal bovine serum, 100 units/ml penicillin, and 100 μg/ml streptomycin; ADV-MyrAKT, adenovirus expressing a constitutively active form of AKT tagged with the hemagglutinin epitope under the control of the cytomegalovirus promoter; ADV-LacZ, adenovirus expressing β-galactosidase under the control of the cytomegalovirus promoter; 7-methoxy-4-trifluoromethylcoumarin; pAKT, phosphorylated AKT; MPT, mitochondrial permeability transition; HA, hemagglutinin; PBS, phosphate-buffered saline; GSH, glutathione; PI, propidium iodide; FTY720, 2-amino-2-[4-octylphenyl]-1,3-propaneldiol hydrochloride; LY303511, 2-(4-piperazinyl)-8 phenyl-4H-7-benzopyran-4-one dihydrochloride; DMSO, dimethyl sulfoxide; AM, acetoxymethyl ester; PD98059, 2′-amino-3′-methoxyflavone; FBS, fetal bovine serum; SB203580, 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole; GSK-3β, glycogen synthase kinase 3β; LY294002, 2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride.
- Received February 13, 2006.
- Accepted April 18, 2006.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|